Hypertension is the medical term for high blood pressure. Persistent high blood pressure can lead to increased strain to the heart and arteries that can eventually cause organ damage.
To classify the blood pressure, it must be based on ≥2 properly measured, seated blood pressure readings on each of ≥2 office visits.
Goals of therapy are to manage hypertension that can maintain the patient's normal blood pressure and identify and treat all reversible risk factors.
In the management of patients with high blood pressure (BP) or resistant hypertension, calcium channel blockers (CCB) confer a more favourable benefit than hydrochlorothiazide when added to an angiotensin converting enzyme (ACE) inhibitor, according to a posthoc analysis of the of the ACCOMPLISH trial.
New drug applications approved by US FDA as of 01 - 15 November 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Tuberculosis (TB) patients with high blood pressure are at increased risk of death during the 9 months following initiation of treatment, a study has found. But the good news is that dihydropyridine calcium channel blockers (DHP-CCBs) may improve survival outcomes.
A new network meta-analysis shines a spotlight on the Dietary Approach to Stop Hypertension (DASH) diet as the most effective nondrug intervention to control blood pressure in adults with prehypertension to established hypertension. Interventions such as aerobic exercise, isometric training, salt restriction, breathing control, and meditation are also helpful.
Heavy periods appear to have a bidirectional relationship with chronic hypertension among young women, such that the former is associated with subsequent risk of the latter and vice versa, according to a study.
Poor adherence to at least one antihypertensive medication (AHM) is prevalent in an Asian population with hypertension, with comorbidity significantly contributing to medication adherence (MA), according to a Singapore study.
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.
A dietary pattern (DP) characterized by high intakes of eggs, fish, milk, and other dairy products appears to confer protective benefits against incident cardiovascular disease (CVD) in women, reveals a study.